Furthermore, the European Medicines Agency (EMA) has approved the use of nivolumab and pembrolizumab for the first-line treatment of advanced HER2-negative esophagogastric adenocarcinoma in combination with a platinum and fluoropyrimidine [20, 22]. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.